Atossa Genetics Inc (NASDAQ:ATOS) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Analysts have set a twelve-month consensus target price of $7.00 for the company and are anticipating that the company will post ($0.65) earnings per share for the current quarter, according to Zacks. Zacks has also given Atossa Genetics an industry rank of 65 out of 255 based on the ratings given to related companies.
A number of equities analysts have weighed in on ATOS shares. Maxim Group reaffirmed a “buy” rating and set a $5.00 price target on shares of Atossa Genetics in a research report on Wednesday, November 14th. ValuEngine cut Atossa Genetics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 29th.
A hedge fund recently raised its stake in Atossa Genetics stock. Virtu Financial LLC lifted its stake in shares of Atossa Genetics Inc (NASDAQ:ATOS) by 405.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 69,903 shares of the company’s stock after purchasing an additional 56,064 shares during the period. Virtu Financial LLC owned 1.24% of Atossa Genetics worth $71,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.06% of the company’s stock.
NASDAQ:ATOS opened at $1.62 on Thursday. Atossa Genetics has a twelve month low of $0.80 and a twelve month high of $9.96.
Atossa Genetics (NASDAQ:ATOS) last released its quarterly earnings results on Tuesday, November 13th. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.01. On average, sell-side analysts anticipate that Atossa Genetics will post -5.13 earnings per share for the current fiscal year.
About Atossa Genetics
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
Further Reading: Understanding Compound Annual Growth Rate (CAGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.